Physician profile
Tabitha Jones
NPI 1336630847
$3,865.30
in general payments reported to CMS, 2019-2025
41 companies · $1,470 in 2025
The $1,470 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $63.35 · 2022: $400 · 2023: $660 · 2024: $1,271 · 2025: $1,470.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,402.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,401.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $544.70 | 2022-2025 | Enhertu, Injectafer, Datroway |
| Novartis Pharmaceuticals Corporation | $486.36 | 2023-2025 | |
| Astrazeneca Pharmaceuticals Lp | $374.24 | 2023-2025 | Calquence, Lynparza, Imfinzi |
| Janssen Biotech, INC. | $335.95 | 2023-2025 | Darzalex, Talvey, Imbruvica |
| Glaxosmithkline, LLC. | $214.21 | 2022-2025 | Jemperli, Zejula, Ojjaara |
| Eisai INC. | $204.14 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $183.19 | 2023-2025 | Keytruda, Welireg, Lynparza |
| Pfizer INC. | $128.87 | 2023-2025 | |
| Agios Pharmaceuticals, INC. | $123.26 | 2022-2024 | Pyrukynd |
| Alexion Pharmaceuticals, INC. | $115.23 | 2023-2025 | Ultomiris |
| Rigel Pharmaceuticals, INC. | $107.78 | 2023-2024 | Tavalisse, Rezlidhia |
| Global Blood Therapeutics, INC. | $99.62 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $93.44 | 2023-2025 | Libtayo |
| Bayer Healthcare Pharmaceuticals INC. | $91.22 | 2023-2025 | |
| Stemline Therapeutics INC. | $79.85 | 2023-2025 | Orserdu |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exelixis INC. | $48.84 | 2024-2025 | Cabometyx |
| Progenics Pharmaceuticals, INC. | $42.19 | 2024 | |
| Sobi, INC | $39.94 | 2022-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $38.63 | 2024-2025 | Iclusig |
| Pharmacosmos Therapeutics INC. | $38.35 | 2024-2025 | Monoferric |
| Recordati_rare_diseases_inc. | $38.13 | 2025 | Sylvant |
| Emmaus Medical, INC. | $37.51 | 2023-2025 | Endari |
| Beone Medicines USA, INC. | $37.07 | 2025 | Brukinsa |
| Genentech USA, INC. | $32.13 | 2024 | Phesgo, Tecentriq, Tecentriq Hybreza |
| Incyte Corporation | $29.80 | 2025 | Zynyz |
| G1 Therapeutics, INC. | $29.12 | 2022 | |
| Genzyme Corporation | $26.84 | 2024 | |
| Seagen INC. | $26.60 | 2023 | Adcetris |
| Tempus Ai, INC | $19.09 | 2025 | Xt Cdx |
| Pharmaessentia USA Corporation | $18.63 | 2025 | Besremi |
| Karyopharm Therapeutics INC. | $18.59 | 2025 | Xpovio |
| E.R. Squibb & Sons, L.L.C. | $18.56 | 2022 | |
| Beigene USA, INC. | $18.23 | 2025 | Brukinsa |
| Azurity Pharmaceuticals, INC. | $17.37 | 2024 | Vivimusta |
| Array Biopharma INC | $17.23 | 2024 | Mektovi, Tukysa, Braftovi |
| Astellas Pharma US INC | $16.85 | 2025 | Vyloy |
| Taiho Oncology, INC. | $15.40 | 2023 | |
| Secura Bio, INC. | $15.22 | 2024 | Copiktra |
| Celgene Corporation | $14.86 | 2025 | Reblozyl |
| Deciphera Pharmaceuticals INC. | $14.45 | 2025 | Qinlock, Romvimza |
| Genmab U.S., INC. | $13.61 | 2023 | Tivdak |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tabitha Jones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.